MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$605,306
Net Income
-$4,749,883
Net Profit Margin
-784.71%
EPS
-$0.57
Unit: Dollar
Revenue Breakdown
Product
Service
Revenue Breakdown
Therapeutic Dna Production
Dna Tagging And Security Product...
Revenue Breakdown
Large Scale Dna Production
Supply Chain
Research And Development Service...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
605,306
1,024,111
565,394
534,233.75*
Cost of product revenues
158,184
197,325
250,037
324,507*
Gross profit
447,122
826,786
315,357
209,726.75*
Selling, general and administrative
2,139,964
2,591,647
13,348,510
2,717,147.5*
Realized gain on derivative written call options
40,272
21,573
-
-
Loss from change in fair value of digital assets
-502,687
-2,086,347
-1,732,557
-
Loss from fair value measurement of investment in digital asset trust
-875,632
-2,548,799
-3,484,009
-
Research and development
209,830
372,149
458,562
1,504,228*
Total operating expenses
3,687,841
7,577,369
19,023,638
4,221,375.5*
Loss from operations
-3,240,719
-6,750,583
-18,708,281
-4,011,648.75*
Interest income
793
3,761
9,143
48,228.75*
Unrealized gain on change in fair value of warrants classified as a liability
-
-
-370
-79,907.5*
Other income (expense), net
-
81,663
92,586
-26,645*
Warrant inducement expense
1,439,652
-
-
-
Loss before provision for income taxes
-4,679,578
-6,665,159
-18,606,182
-3,910,157.5*
Income tax provision benefit
-
-
-
-171,028.75*
Net loss from continuing operations
-4,679,578
-6,665,159
-18,606,182
-3,739,128.75*
Clinical laboratory service revenues
-
-
-
143,232*
Cost of clinical laboratory service revenues
-
-
-
197,613.75*
Gross profit
-
-
-
-54,381.75*
Selling, general and administrative
-
-
-
53,776.25*
Interest (income)
-
-
-
825.25*
Other expense, net
-
-
-
9,150*
Net loss from discontinued operations
-
-
-
-98,182.75
Net loss from discontinued operations, net of tax
-
-
-
-98,182.75*
Net loss
-4,679,578
-6,665,159
-18,606,182
-3,837,311.5*
Less net (income) loss attributable to noncontrolling interest
6,727
68
-12,619
-47,130.5*
Net loss attributable to bnb plus corp
-4,686,305
-6,665,227
-18,593,563
-3,790,181*
Deemed dividend related to warrant modifications
43,944
-
32,827
13,581,724*
Cumulative dividends on series b-1 and b-2 preferred stock
19,634
-
-
-
Net loss attributable to common stockholders
-4,749,883
-6,665,227
-18,626,390
-17,371,905
Basic EPS
-0.57
-0.68
-2.08
-33.558
Diluted EPS
-0.57
-0.68
-2.08
-33.558
Basic Average Shares
8,365,055
9,735,631
8,942,937
517,671
Diluted Average Shares
8,365,055
9,735,631
8,942,937
517,671
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
Net loss
attributable to common...
-$4,749,883
Net loss
attributable to bnb plus corp
-$4,686,305
Deemed dividend
related to warrant...
$43,944
Cumulative dividends on
series b-1 and b-2...
$19,634
Net loss
-$4,679,578
Less net (income)
loss attributable to...
$6,727
Therapeutic Dna Production
$584,663
Dna Tagging And
Security Products
$888
Dna Tagging And
Security Products
$21,018
Net loss from
continuing operations
-$4,679,578
Product
$585,551
Service
$19,755
Therapeutic Dna Production
-$1,263
Loss before
provision for income taxes
-$4,679,578
Interest income
$793
Total revenues
$605,306
Loss from operations
-$3,240,719
Warrant inducement
expense
$1,439,652
Gross profit
$447,122
Cost of product
revenues
$158,184
Total operating
expenses
$3,687,841
Realized gain on
derivative written call...
$40,272
Selling, general and
administrative
$2,139,964
Loss from fair value
measurement of investment in...
-$875,632
Loss from change in
fair value of digital...
-$502,687
Research and development
$209,830
Buy us a coffee
BNB PLUS CORP. (BNBX)
BNB PLUS CORP. (BNBX)